In the third quarter of 2008, ev3's neurovascular segment net sales increased 26% to $33.1 million versus $26.4 million in the third quarter of 2007. Within the neurovascular business segment, sales of embolic products increased 24% to $18.2 million from $14.7 million, and sales of neurovascular access and delivery products were up 28% to $14.9 million from $11.7 million.
Research collaboration revenue resulting from ev3's former collaboration and license agreement with Merck & Co., Inc. was $7.0 million for the third quarter of 2008, which included approximately $2.0 million for wind-down activities as negotiated with Merck. ev3 expects to recognize approximately $800,000 of additional revenue from wind-down activities in the fourth quarter of 2008.
On a geographic basis, when compared to the third quarter of 2007,
ev3's third quarter 2008 U.S. net sales increased 84% to $70.4 million,
while third quarter 2008 international net sales increased 37% to $36.6
million, over the prior-year quarter. ev3's third quarter 2008 U.S. net
sales increase was primarily due to the FoxHollow acquisition.
International sales growth was primarily due to the Axium coil, further
market penetration of the EverFlex family of stents and the Onyx Liquid
Embolic System for the treatment of brain arterio-venous malformations
(AVMs), and the introduction of atherectomy products into international
markets. Changes in foreign currency exchange rates had a positive impact
of approximately $1.7 million on third quarter 2
|SOURCE ev3 Inc.|
Copyright©2008 PR Newswire.
All rights reserved